{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T02:51:47Z","timestamp":1773370307806,"version":"3.50.1"},"reference-count":14,"publisher":"Instituto Nacional de Salud (Colombia)","issue":"Sp. 1","license":[{"start":{"date-parts":[[2024,5,31]],"date-time":"2024-05-31T00:00:00Z","timestamp":1717113600000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,5,31]],"date-time":"2024-05-31T00:00:00Z","timestamp":1717113600000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["revistabiomedica.org"],"crossmark-restriction":false},"short-container-title":["Biomed."],"abstract":"<jats:p>Introducci\u00f3n. El consenso internacional y la gu\u00eda del 2019 de la American Society of Hematology, establecieron a los an\u00e1logos de la trombopoyetina como medicamentos de segunda l\u00ednea para tratar la trombocitopenia inmunitaria primaria. En Ecuador, se comercializan dos trombomim\u00e9ticos: romiplostim y eltrombopag.Objetivos. Describir el uso de romiplostim en pacientes con trombocitopenia inmunitaria, en un hospital de tercer nivel en Cuenca (Ecuador).Materiales y m\u00e9todos. Se adelant\u00f3 un estudio descriptivo y retrospectivo en pacientes con trombocitopenia inmunitaria y tratamiento con romiplostim. Se evaluaron las siguientes variables: edad, sexo, tratamientos previos a romiplostim, dosis, frecuencia, complicaciones, cambio de an\u00e1logo de trombopoyetina y discontinuaci\u00f3n de la terapia.Resultados. Veinti\u00fan pacientes con trombocitopenia inmunitaria fueron tratados con romiplostim, con una mediana de 49 a\u00f1os. Todos recibieron corticoides como tratamiento de primera l\u00ednea. Tres precisaron de intervalos m\u00e1s prolongados que el semanal, con dosis semanales menores de las recomendadas (&lt; 1 \u03bcg\/kg). Por falta de eficacia, en seis pacientes se reemplaz\u00f3 la terapia con eltrombopag por romiplostim. Tres pacientes padecieron complicaciones tromb\u00f3ticas: dos, trombosis venosa portal, y uno, tromboembolia pulmonar. En cinco, se discontinu\u00f3 el tratamiento con romiplostim, sin necesidad de reanudarlo.Conclusiones. Romiplostim constituye un tratamiento de segunda l\u00ednea para la trombocitopenia inmunitaria primaria. A pesar del reducido tama\u00f1o de la muestra, se observ\u00f3 que la administraci\u00f3n temprana del medicamento puede minimizar toxicidades y riesgos infecciosos.<\/jats:p>","DOI":"10.7705\/biomedica.7059","type":"journal-article","created":{"date-parts":[[2024,7,30]],"date-time":"2024-07-30T15:40:41Z","timestamp":1722354041000},"page":"198-204","update-policy":"https:\/\/doi.org\/10.7705\/crossmark","source":"Crossref","is-referenced-by-count":2,"title":["Uso de romiplostim en trombocitopenia inmunitaria: experiencia en Cuenca (Ecuador)","Romiplostim use in immune thrombocytopenia: Experience in Cuenca, Ecuador"],"prefix":"10.7705","volume":"44","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4157-2411","authenticated-orcid":false,"given":"H\u00e9ctor","family":"Chiang-Wong","sequence":"first","affiliation":[{"name":"Unidad de Hematolog\u00eda, Hospital Jos\u00e9 Carrasco Arteaga, Cuenca, Ecuador"},{"name":"Unidad de Hematolog\u00eda, Hospital Jos\u00e9 Carrasco Arteaga, Cuenca, Ecuador"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7043-2894","authenticated-orcid":false,"given":"Patricio","family":"Gonz\u00e1lez-Salda\u00f1a","sequence":"additional","affiliation":[{"name":"Unidad de Patolog\u00eda Cl\u00ednica, Hospital Jos\u00e9 Carrasco Arteaga, Cuenca, Ecuador"},{"name":"Unidad de Patolog\u00eda Cl\u00ednica, Hospital Jos\u00e9 Carrasco Arteaga, Cuenca, Ecuador"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"4444","published-online":{"date-parts":[[2024,5,31]]},"reference":[{"key":"135816","unstructured":"\u00c1lvarez-Rom\u00e1n MT, Berrueco-Moreno R, Canaro-Hirnyk M, Entrena-Ure\u00f1a L, Fern\u00e1ndez-Fuertes F, Gonz\u00e1lez-L\u00f3pez T, et al. Directrices de diagn\u00f3stico, tratamiento y seguimiento de la PTI. Recomendaciones del Grupo de Trabajo de la SEHH y GEPTI. Primera edici\u00f3n. Madrid: Sociedad Espa\u00f1ola de Hematolog\u00eda y Hemoterapia; 2020."},{"key":"135817","doi-asserted-by":"crossref","unstructured":"Zychowicz A, Radkowiak, D Lasek A, Malczak P, Witowsky J, Major P, et al. Laparoscopic splenectomy for thrombocytopenia immune in patients with a very low platelet count. Videosurgery Miniinv. 2018;13:157-63. https:\/\/doi.org\/10.5114\/wiitm.2018.75847","DOI":"10.5114\/wiitm.2018.75847"},{"key":"135818","doi-asserted-by":"crossref","unstructured":"Deshayes S, Khellaf M, Zarour A, Layese R, Fain O, Terriou L, et al. Long-term safety and efficacy of rituximab in 248 adults with immune thrombocytopenia: Results at 5 years from the French prospective registry ITP-ritux. Am J Hematol. 2019;94:1314-24. https:\/\/doi.org\/10.1002\/ajh.25632","DOI":"10.1002\/ajh.25632"},{"key":"135819","doi-asserted-by":"crossref","unstructured":"Gonz\u00e1lez-Porras J, Godeau B, Carpenedo M. Switching thrombopoietin receptor agonist treatments in patients with primary immune thrombocytopenia. Ther Adv Hematol. 2019;10:2040620719837906. https:\/\/doi.org\/10.1177\/2040620719837906","DOI":"10.1177\/2040620719837906"},{"key":"135820","doi-asserted-by":"crossref","unstructured":"\u00c1lvarez-Rom\u00e1n MT, Fern\u00e1ndez-Bello I, Arias-Salgado EG, Rivas-Pollmar MI, Jim\u00e9nez-Yuste V, Mart\u00edn-Salces M, et al. Effects of thrombopoietin receptor agonists on procoagulant state in patients with immune thrombocytopenia. Thromb Haemost. 2014;112:65-72. https:\/\/doi.org\/10.1160\/TH13-10-0873","DOI":"10.1160\/TH13-10-0873"},{"key":"135821","doi-asserted-by":"crossref","unstructured":"Provan D, Arnold D, Bussel J, Chong B, Cooper N, Gernsheimer T, et al. Updated international consensus report on the investigation and management of primary immune thrombocytopenia. Blood Adv. 2019;3:3780-817. https:\/\/doi.org\/10.1182\/bloodadvances.2019000812","DOI":"10.1182\/bloodadvances.2019000812"},{"key":"135822","doi-asserted-by":"crossref","unstructured":"Ghanima W, Cooper N, Rodeghiero F, Godeau B, Bussel J. Thrombopoietin receptor agonists: Ten years later. Haematologica. 2018;104:1112-23. https:\/\/doi.org\/10.3324\/haematol.2018.212845","DOI":"10.3324\/haematol.2018.212845"},{"key":"135823","doi-asserted-by":"crossref","unstructured":"Kuter DJ, Newland A, Chong B, Rodeghiero F, Romero M, Pabinger I, et al. Romiplostim in adult patients with newly diagnosed or persistent immune thrombocytopenia (ITP) for up to 1 year and in those with chronic ITP for more than 1 year: A subgroup analysis of integrated data from completed Romiplostim studies. Br J Haematol. 2019;3:503-13. https:\/\/doi.org\/10.1111\/bjh.15803","DOI":"10.1111\/bjh.15803"},{"key":"135824","doi-asserted-by":"crossref","unstructured":"Ito S, Fujiwara S, Ikeda T, Toda Y, Mashima K, Umino K, et al. Evaluation of thrombotic events in patients with immune thrombocytopenia. Ann Hematol. 2020;99:49-55. https:\/\/doi.org\/10.1007\/s00277-019-03886-6","DOI":"10.1007\/s00277-019-03886-6"},{"key":"135825","doi-asserted-by":"crossref","unstructured":"Janssens A, Rodeghiero F, Anderson D, Chong B, Boda Z, Pabinger I, et al. Changes in bone marrow morphology in adults receiving Romiplostim for the treatment of thrombocytopenia associated with primary immune thrombocytopenia. Ann Hematol. 2016;95:1077-108. https:\/\/doi.org\/10.1007\/s00277-016-2682-2","DOI":"10.1007\/s00277-016-2682-2"},{"key":"135826","doi-asserted-by":"crossref","unstructured":"Zaja F, Carpenedo M, Barate C, Borchiellini A, Chiurazzi F, Finazzi G, et al. Tapering and discontinuation of thrombopoietin receptor agonists in immune thrombocytopenia: Realworld recommendations. Blood Rev. 2020;41:100647. https:\/\/doi.org\/10.1016\/j.blre.2019.100647","DOI":"10.1016\/j.blre.2019.100647"},{"key":"135827","doi-asserted-by":"crossref","unstructured":"Cooper N, Hill Q, Grainger J, Westwod J, Bradbury C, Provan D, et al. Tapering and discontinuation of thrombopoietin receptor agonist therapy in patients with immune thrombocytopenia: Results from a modified Delphi Panel. Acta Haematol. 2021;144:418-26. https:\/\/doi.org\/10.1159\/000510676","DOI":"10.1159\/000510676"},{"key":"135828","doi-asserted-by":"crossref","unstructured":"Neunert C, Terrel D, Arnold D, Buchanan G, Cines D, Cooper N, et al. American Society of Hematology 2019 guidelines for immune thrombocytopenia. Blood Adv. 2019;3:3829-66. https:\/\/doi.org\/10.1182\/bloodadvances.2019000966","DOI":"10.1182\/bloodadvances.2019000966"},{"key":"135829","doi-asserted-by":"crossref","unstructured":"Lino M, Sakamoto Y, Sato T. Treatmentfree remission after thrombopoietin receptor agonist discontinuation in patients with newly diagnosed immune thrombocytopenia: An observational retrospective analysis in realworld clinical practice. Int J Hematol. 2020;112:159-68. https:\/\/doi.org\/10.1007\/s12185-020-02893-y","DOI":"10.1007\/s12185-020-02893-y"}],"container-title":["Biom\u00e9dica"],"original-title":[],"link":[{"URL":"https:\/\/revistabiomedica.org\/index.php\/biomedica\/article\/download\/7059\/5547","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/revistabiomedica.org\/index.php\/biomedica\/article\/download\/7059\/5629","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/revistabiomedica.org\/index.php\/biomedica\/article\/download\/7059\/5547","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T14:13:28Z","timestamp":1773324808000},"score":1,"resource":{"primary":{"URL":"https:\/\/revistabiomedica.org\/index.php\/biomedica\/article\/view\/7059"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,31]]},"references-count":14,"journal-issue":{"issue":"Sp. 1","published-online":{"date-parts":[[2024,5,31]]}},"URL":"https:\/\/doi.org\/10.7705\/biomedica.7059","relation":{},"ISSN":["2590-7379","0120-4157"],"issn-type":[{"value":"2590-7379","type":"electronic"},{"value":"0120-4157","type":"print"}],"subject":[],"published":{"date-parts":[[2024,5,31]]},"assertion":[{"value":"2024-05-31","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}},{"value":"Yes","order":0,"name":"peer_reviewed","label":"Peer Reviewed","group":{"name":"peer_review","label":"Peer Review"}},{"value":"Instituto Nacional de Salud","name":"publisher","label":"This article is maintained by"},{"value":"Biomedica","name":"journaltitle","label":"Journal Title"},{"value":"Comunicaci\u00f3n breve","name":"content_type","label":"Content Type"}]}}